Sterile Filling and Closing Equipment Handles Vials and Cartridges
Bosch Packaging Technology ? Business Unit Pharma is one of the leading providers of process technology and packaging solutions for the pharmaceutical industry. The portfolio includes single units, integrated systems and complete solutions for the manufacturing and processing of sterile and non sterile liquids and powders.
The new filling and closing machine FXS Combi
Depending on output and container, the new filling and closing machine FXS Combi with two or five positions processes pre-sterilized nested syringes, vials and cartridges. The FXS Combi is the first filling and closing machine of this kind with an integrated capping station for vials and cartridges. It can be easily integrated into line concepts, allowing for significant space savings. The FXS Combi is suited for low and medium output rates.
The FXS Combi operates with a combi filling station with up to six dosing heads. This makes the machine suitable for all common filling technologies, such as peristaltic or rotary slide valve piston pumps as well as the single-use filling technology PreVAS. A combination with different barrier systems is also possible; the FXS Combi is suited for both Restricted Access Barrier Systems (RABS) and isolators. By combining the new filling and closing machine with the proven upstream ATO tub opener and ABO bag opener from Bosch, it can be integrated into fully automated line concepts.
Robert Bosch GmbH, Packaging Technology division
Website: www.boschpackaging.com
E-mail:
packaging@bosch.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
